In brief
The Trump administration's recent decision to cut billions in overhead funding for biomedical research grants has sparked outrage among scientific communities, who warn of the potential harms to critical health research.
President Donald Trump’s administration revealed plans to slash billions of dollars from biomedical research overhead funding as part of broader budget reduction efforts. The National Institutes of Health (NIH) made the announcement, stating that the decision is aimed at allocating more funds toward direct scientific research rather than administrative expenses. The cuts will cap indirect costs at 15 percent, significantly lowered from the current average of 30 percent. This move is expected to save around $4 billion and will take effect immediately.Elon Musk, head of the Department of Government Efficiency (Doge), claimed on social media that many universities are misusing substantial portions of research grants for overhead expenses, stating that some universities could be taking up to 60% for indirect costs. Despite these claims, numerous researchers argue that these funds are essential to sustaining vital laboratory operations. The Association of American Medical Colleges voiced concerns that this funding reduction will impair the nation’s research capabilities, ultimately slowing medical progress and endangering new treatment developments.Prominent researchers like Anusha Kalbasi from Stanford University emphasized that cutting overhead support would hinder critical infrastructure and safety measures within labs. Meanwhile, the American Council on Education warned that the inability to uphold advanced laboratories could lead to diminished research competitiveness globally. In reaction to the cuts, there are indications that some institutions may pursue legal action to challenge the funding redistribution as they brace for system-wide shutdowns due to the financial restrictions. These measures are seen as part of a conservative agenda outlined in Project 2025, which includes proposals to limit the funding rates for universities based on private sector benchmarks. Critics warn that these changes could have long-lasting repercussions on the medical research landscape amid ongoing global challenges.
